論文

2020 英文

TITLE & JOURNAL/AUTHORS

• Role of cytoglobin, a novel radical scavenger, in stellate cell activation and hepatic fibrosis
  著者名：Thuy LTT, Hai H, Kawada N.
  出版物名：Clin Mol Hepatol. 2020 Jun 4. doi: 10.3350/cmh.2020.0037. Online ahead of print.
• The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease
  著者名：Fujii H, Kawada N, Japan Study Group Of Nafld Jsg-Nafld.
  出版物名：Int J Mol Sci. 2020 May 29;21(11):E3863. doi: 10.3390/ijms21113863.
• Association of serum autotaxin levels with liver fibrosis in patients pretreatment and posttreatment with chronic hepatitis C
  著者名：Takemura K, Takizawa E, Tamori A, Nakamae M, Kubota H, Uchida-Kobayashi S, Enomoto M, Kawada N, Hino M.
  出版物名：J Gastroenterol Hepatol. 2020 May 26. doi: 10.1111/jgh.15114. Online ahead of print.
• Serum Mac-2-binding protein glycosylation isomer predicts esophagogastric varices in cirrhotic patients with chronic hepatitis C virus infection treated with IFN-free direct-acting antiviral agent: M2BPGi levels predict varices in SVR patients
  著者名：Kikukawa K, Uchida-Kobayashi S, Tamori A, Yoshida K, Kotani K, Motoyama H, Kozuka R, Hagihara A, Fujii H, Morikawa H, Enomoto M, Murakami Y, Kawada N.
  出版物名：Ann Hepatol. 2020 May 11:S1665-2681(20)30039-9. doi: 10.1016/j.aohep.2020.04.002. Online ahead of print.
• Clinical course of COVID-19 in patients with pre-existing decompensated cirrhosis: initial report from China
  著者名：Qi X, Wang J, Li X, Wang Z, Liu Y, Yang H, Li X, Shi J, Xiang H, Liu T, Kawada N, Maruyama H, Jiang Z, Wang F, Takehara T, Rockey DC, Sarin SK; COVID-Cirrhosis-CHESS Group.
  出版物名：Hepatol Int. 2020 May 22:1-5. doi: 10.1007/s12072-020-10051-z. Online ahead of print.
• A validation study of the Ursodeoxycholic Acid Response Score in Japanese patients with primary biliary cholangitis
  著者名：Yagi M, Matsumoto K, Komori A, Abe M, Hashimoto N, Inao M, Namisaki T, Kawata K, Ninomiya M, Fujii H, Takahashi A, Kang JH, Takamura M, Arakawa M, Joshita S, Sato K, Itakura J, Nomura T, Kakisaka K, Kaneko A, Tamura Y, Miura R, Aiso M, Arizumi T, Asaoka Y, Kikuchi K, Takikawa Y, Masaki T, Umemura T, Honda A, Ohira H, Kawada N, Yoshiji H, Mochida S, Takikawa H, Tanaka A; Japan PBC Study Group (JPBCSG).
  出版物名：Liver Int. 2020 May 21. doi: 10.1111/liv.14534. Online ahead of print.
• Clinical course and risk factors for mortality of COVID-19 patients with pre-existing cirrhosis: a multicentre cohort study
  著者名：Qi X, Liu Y, Wang J, Fallowfield JA, Wang J, Li X, Shi J, Pan H, Zou S, Zhang H, Chen Z, Li F, Luo Y, Mei M, Liu H, Wang Z, Li J, Yang H, Xiang H, Li X, Liu T, Zheng MH, Liu C, Huang Y, Xu D, Li X, Kang N, He Q, Gu Y, Zhang G, Shao C, Liu D, Zhang L, Li X, Kawada N, Jiang Z, Wang F, Xiong B, Takehara T, Rockey DC; COVID-Cirrhosis-CHESS Group.
  出版物名：Gut. 2020 May 20:gutjnl-2020-321666. doi: 10.1136/gutjnl-2020-321666. Online ahead of print.
• TGF-β1-driven reduction of cytoglobin leads to oxidative DNA damage in stellate cells during non-alcoholic steatohepatitis
  著者名：Okina Y, Sato-Matsubara M, Matsubara T, Daikoku A, Longato L, Rombouts K, Thanh Thuy LT, Ichikawa H, Minamiyama Y, Kadota M, Fujii H, Enomoto M, Ikeda K, Yoshizato K, Pinzani M, Kawada N.
  出版物名：J Hepatol. 2020 Apr 17:S0168-8278(20)30228-2. doi: 10.1016/j.jhep.2020.03.051. Online ahead of print.
• Long-term outcome of pediatric non-cirrhotic portal fibrosis from the viewpoint of endoscopic profile
  著者名：Kotani K, Kawada N.
  出版物名：Hepatol Int. 2020 Mar;14(2):164-166. doi: 10.1007/s12072-020-10028-y. Epub 2020 Mar 13.
• Destructive thyroiditis presenting as thyrotoxicosis followed by hypothyroidism during lenvatinib therapy for hepatocellular carcinoma
  著者名：Suoh M, Fujii H, Nagata Y, Kotani K, Hagihara A, Enomoto M, Tamori A, Inaba M, Kawada N.
  出版物名：Clin J Gastroenterol. 2020 Mar 3. doi: 10.1007/s12328-020-01107-6. Online ahead of print.
• Clinical significance of circulating soluble immune checkpoint proteins in sorafenib-treated patients with advanced hepatocellular carcinoma
  著者名：Dong MP, Enomoto M, Thuy LTT, Hai H, Hieu VN, Hoang DV, Iida-Ueno A, Odagiri N, Amano-Teranishi Y, Hagihara A, Fujii H, Uchida-Kobayashi S, Tamori A, Kawada N.
  出版物名：Sci Rep. 2020 Feb 25;10(1):3392. doi: 10.1038/s41598-020-60440-5.
• Exosomal hsa-miR-933 in Gastric Juice as a Potential Biomarker for Functional Dyspepsia
  著者名：Tanaka F, Takashima S, Nadatani Y, Otani K, Hosomi S, Kamata N, Taira K, Nagami Y, Tanigawa T, Fukumoto S, Watanabe T, Murakami Y, Kawada N, Fujiwara Y.
  出版物名：Dig Dis Sci. 2020 Jan 23. doi: 10.1007/s10620-020-06096-7. Online ahead of print.
• The Administration of Tenofovir Disoproxil Fumarate for Pregnant Japanese Women with Chronic Hepatitis B
  著者名：Suoh M, Tamori A, Amano-Teranishi Y, Nakai T, Enomoto M, Kawasaki Y, Kioka K, Kawada N.
  出版物名：Intern Med. 2020;59(2):205-210. doi: 10.2169/internalmedicine.3504-19. Epub 2020 Jan 15.
• Development of a novel anti-hepatitis B virus agent via Sp1
  著者名：Hayakawa M, Umeyama H, Iwadate M, Taguchi YH, Yano Y, Honda T, Itami-Matsumoto S, Kozuka R, Enomoto M, Tamori A, Kawada N, Murakami Y.
  出版物名：Sci Rep. 2020 Jan 8;10(1):47. doi: 10.1038/s41598-019-56842-9.
• The Antioxidative Role of Cytoglobin in Podocytes: Implications for a Role in Chronic Kidney Disease
  著者名：Randi EB, Vervaet B, Tsachaki M, Porto E, Vermeylen S, Lindenmeyer MT, Thuy LTT, Cohen CD, Devuyst O, Kistler AD, Szabo C, Kawada N, Hankeln T, Odermatt A, Dewilde S, Wenger RH, Hoogewijs D.
  出版物名：Antioxid Redox Signal. 2020 Jun 1;32(16):1155-1171. doi: 10.1089/ars.2019.7868. Epub 2020 Feb 6.
• The Moral of Hepatic Fibrosis: Don't Always Believe Noninvasive Fibrosis Measurements
  著者名：Enomoto M, Kawada N.
  出版物名：Dig Dis Sci. 2020 May;65(5):1293-1295. doi: 10.1007/s10620-019-06035-1.
• Cure With Interferon-Free Direct-Acting Antiviral Is Associated With Increased Survival in Patients With Hepatitis C Virus-Related Hepatocellular Carcinoma From Both East and West
  著者名：Dang H, Yeo YH, Yasuda S, Huang CF, Iio E, Landis C, Jun DW, Enomoto M, Ogawa E, Tsai PC, Le A, Liu M, Maeda M, Nguyen B, Ramrakhiani N, Henry L, Cheung R, Tamori A, Kumada T, Tanaka Y, Yu ML, Toyoda H, Nguyen MH.
  出版物名：Hepatology. 2020 Jun;71(6):1910-1922. doi: 10.1002/hep.30988. Epub 2020 May 8.
• Hepatitis B Core-Related Antigen to Indicate High Viral Load: Systematic Review and Meta-Analysis of 10,397 Individual Participants
  著者名：Yoshida K, Desbiolles A, Feldman SF, Ahn SH, Alidjinou EK, Atsukawa M, Bocket L, Brunetto MR, Buti M, Carey I, Caviglia GP, Chen EQ, Cornberg M, Enomoto M, Honda M, Zu Siederdissen CH, Ishigami M, Janssen H, Maasoumy B, Matsui T, Matsumoto A, Nishiguchi S, Riveiro-Barciela M, Takaki A, Tangkijvanich P, Toyoda H, van Campenhout MJ, Wang B, Wei L, Yang HI, Yano Y, Yatsuhashi H, Yuen MF, Tanaka E, Lemoine M, Tanaka Y, Shimakawa Y.
  出版物名：Clin Gastroenterol Hepatol. 2020 Apr 29:S1542-3565(20)30590-5. doi: 10.1016/j.cgh.2020.04.045. Online ahead of print.
• Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B
  著者名：Hsu YC, Wong GL, Chen CH, Peng CY, Yeh ML, Cheung KS, Toyoda H, Huang CF, Trinh H, Xie Q, Enomoto M, Liu L, Yasuda S, Tanaka Y, Kozuka R, Tsai PC, Huang YT, Wong C, Huang R, Jang TY, Hoang J, Yang HI, Li J, Lee DH, Takahashi H, Zhang JQ, Ogawa E, Zhao C, Liu C, Furusyo N, Eguchi Y, Wong C, Wu C, Kumada T, Yuen MF, Yu ML, Nguyen MH.
  出版物名：Am J Gastroenterol. 2020 Feb;115(2):271-280. doi: 10.14309/ajg.0000000000000428.
• Real-World Effectiveness From the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated With Oral Antiviral Therapy
  著者名：Yang HI, Yeh ML, Wong GL, Peng CY, Chen CH, Trinh HN, Cheung KS, Xie Q, Su TH, Kozuka R, Lee DH, Ogawa E, Zhao C, Ning HB, Huang R, Li J, Zhang JQ, Ide T, Xing H, Iwane S, Takahashi H, Wong C, Wong C, Lin CH, Hoang J, Le A, Henry L, Toyoda H, Ueno Y, Gane EJ, Eguchi Y, Kurosaki M, Wu C, Liu C, Shang J, Furusyo N, Enomoto M, Kao JH, Yuen MF, Yu ML, Nguyen MH.
  出版物名：J Infect Dis. 2020 Jan 14;221(3):389-399. doi: 10.1093/infdis/jiz477.
• Liver injury after methylprednisolone pulse therapy in multiple sclerosis is usually due to idiosyncratic drug-induced toxicity rather than autoimmune hepatitis
  著者名：Kimura H, Takeda A, Kikukawa T, Hasegawa I, Mino T, Uchida-Kobayashi S, Ohsawa M, Itoh Y.
  出版物名：Mult Scler Relat Disord. 2020 Jul;42:102065. doi: 10.1016/j.msard.2020.102065. Epub 2020 Mar 23.
• Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis
  著者名：Sumida Y, Yoneda M, Tokushige K, Kawanaka M, Fujii H, Yoneda M, Imajo K, Takahashi H, Eguchi Y, Ono M, Nozaki Y, Hyogo H, Koseki M, Yoshida Y, Kawaguchi T, Kamada Y, Okanoue T, Nakajima A, Jsg-Nafld JSGON.
  出版物名：Int J Mol Sci. 2020 Mar 11;21(6):1907. doi: 10.3390/ijms21061907.
• Twelve weeks of ledipasvir/sofosbuvir all-oral regimen for patients with chronic hepatitis C genotype 2 infection: Integrated analysis of three clinical trials
  著者名：Asahina Y, Liu CJ, Gane E, Itoh Y, Kawada N, Ueno Y, Youn J, Wang CY, Llewellyn J, Matsuda T, Gaggar A, Mo H, Dvory-Sobol H, Crans G, Chuang WL, Chen PJ, Enomoto N.
  出版物名：Hepatol Res. 2020 Jul 2. doi: 10.1111/hepr.13546. Online ahead of print.
• Post-Treatment M2BPGi Level and the Rate of Autotaxin Reduction are Predictive of Hepatocellular Carcinoma Development after Antiviral Therapy in Patients with Chronic Hepatitis C
  著者名：Takemura K, Takizawa E, Tamori A, Nakamae M, Kubota H, Uchida-Kobayashi S, Enomoto M, Kawada N, Hino M.
  出版物名：Int J Mol Sci. 2020 Jun 25;21(12):4517. doi: 10.3390/ijms21124517.
• Lenvatinib-Induced Tumor-Related Hemorrhage in Patients With Unresectable Hepatocellular Carcinoma
  著者名：Kotani K, Uchida-Kobayashi S, Yoshida K, Kawamura E, Fujii H, Hagihara A, Enomoto M, Tamori A, Kawada N.
  出版物名：Am J Gastroenterol. 2020 Jul 14. doi: 10.14309/ajg.0000000000000747. Online ahead of print.
• Early Change in the Plasma Levels of Circulating Soluble Immune Checkpoint Proteins in Patients with Unresectable Hepatocellular Carcinoma Treated by Lenvatinib or Transcatheter Arterial Chemoembolization
  著者名：Odagiri N, Hai H, Thuy LTT, Dong MP, Suoh M, Kotani K, Hagihara A, Uchida-Kobayashi S, Tamori A, Enomoto M, Kawada N.
  出版物名：Cancers (Basel). 2020 Jul 24;12(8):2045.
• Plasma xanthine oxidoreductase activity change over 12 months independently associated with change in serum uric acid level: MedCity21 health examination registry
  著者名：Kurajoh M, Fukumoto S, Murase T, Nakamura T, Nagata Y, Nakatani S, Tsuda A, Yamada S, Morioka T, Mori K, Imanishi Y, Kawada N, Hirata K, Emoto M.
  出版物名：Clin Chem Lab Med. 2020 Jul 29:/j/cclm.ahead-of-print/cclm-2020-0563/cclm-2020-0563.xml. doi: 10.1515/cclm-2020-0563. Online ahead of print.
• Utility of minimally invasive measurement of hepatic venous pressure gradient via the peripheral antecubital vein
  著者名：Yamamoto A, Kawada N, Jogo A, Murai K, Kotani K, Kageyama K, Hamamoto S, Sohgawa E, Uchida-Kobayashi S, Enomoto M, Tamori A, Miki Y.
  出版物名：Gut. 2020 Aug 18;gutjnl-2020-322367. doi: 10.1136/gutjnl-2020-322367. Online ahead of print.
• Surgical outcomes for hepatocellular carcinoma detected after hepatitis C virus eradiation by direct-acting antivirals
  著者名：Tanaka S, Shinkawa H, Tamori A, Takemura S, Takahashi S, Amano R, Kimura K, Ohira G, Kawada N, Kubo S.
  出版物名：J Surg Oncol. 2020 Aug 27. doi: 10.1002/jso.26184. Online ahead of print.
• Outcome of nucleos(t)ide analog intervention in patients with preventive or on-demand therapy for hepatitis B virus reactivation
  著者名：Tamori A, Kimura K, Kioka K, Enomoto H, Odagiri N, Kozuka R, Uchida-Kobayashi S, Enomoto M, Kawada N, Mizokami M.
  出版物名：J Med Virol. 2020 Sep 17. doi: 10.1002/jmv.26526. Online ahead of print.
• Cytoglobin-expressing cells in the splenic cords contribute to splenic fibrosis in cirrhotic patients
  著者名：Iimuro Y, Yada A, Okada T, Nakamura I, Suzumura K, Xu J, Sudo M, Nishiguchi S, Kawada N, Hatano E, Fujimoto J.
  出版物名：Histol Histopathol. 2020 Sep 18;18257. doi: 10.14670/HH-18-257. Online ahead of print.
• Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study
  著者名：Tahata Y, Hikita H, Mochida S, Kawada N, Enomoto N, Ido A, Yoshiji H, Miki D, Hiasa Y, Takikawa Y, Sakamori R, Kurosaki M, Yatsuhashi H, Tateishi R, Ueno Y, Itoh Y, Yamashita T, Kanto T, Suda G, Nakamoto Y, Kato N, Asahina Y, Matsuura K, Terai S, Nakao K, Shimizu M, Takami T, Akuta N, Yamada R, Kodama T, Tatsumi T, Yamada T, Takehara T.
  出版物名：J Gastroenterol. 2020 Oct 1. doi: 10.1007/s00535-020-01733-4. Online ahead of print.
• Obstructive Jaundice Due to Duodenal Ulcer Induced by Lenvatinib Therapy for Hepatocellular Carcinoma
  著者名：Suoh M, Hagihara A, Yamamura M, Maruyama H, Taira K, Enomoto M, Tamori A, Fujiwara Y, Kawada N.
  出版物名：Intern Med. 2020 Oct 7. doi: 10.2169/internalmedicine.5097-20. Online ahead of print.
• Lenvatinib-Induced Tumor-Related Hemorrhages in Patients with Large Hepatocellular Carcinomas
  著者名：Uchida-Kobayashi S, Kageyama K, Yamamoto A, Ikenaga H, Yoshida K, Kotani K, Kimura K, Odagiri N, Hagihara A, Fujii H, Enomoto M, Tamori A, Kubo S, Miki Y, Kawada N.
  出版物名：Oncology. 2020 Oct 8:1-6. doi: 10.1159/000510911. Online ahead of print.
• Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis
  著者名：Sumida Y, Yoneda M, Tokushige K, Kawanaka M, Fujii H, Yoneda M, Imajo K, Takahashi H, Eguchi Y, Ono M, Nozaki Y, Hyogo H, Koseki M, Yoshida Y, Kawaguchi T, Kamada Y, Okanoue T, Nakajima A, Jsg-Nafld JSGON.
  出版物名：Int J Mol Sci. 2020 Mar 11;21(6):1907. doi: 10.3390/ijms21061907.
• Risk factors for hepatocellular carcinoma in treated chronic hepatitis C patients-Relationship to smoking and alcohol
  著者名：Matsuura T, Ohfuji S, Enomoto M, Tamori A, Kubo S, Kioka K, Kawada N, Fukushima W.
  出版物名：JGH Open. 2020 Apr 16;4(5):867-875. doi: 10.1002/jgh3.12331. eCollection 2020 Oct.
• High dropout rate from aftercare program of antihepatitis C therapy for patients with history of injection drug use
  著者名：Tamori A, Uchida-Kobayashi S, Kozuka R, Motoyama H, Yoshida K, Odagiri N, Kotani K, Kawamura E, Fujii H, Hagihara A, Enomoto M, Kawada N.
  出版物名：JGH Open. 2020 Jun 23;4(5):964-969. doi: 10.1002/jgh3.12376. eCollection 2020 Oct.
• Lifestyles Associated with Prognosis After Eradication of Hepatitis C Virus: A Prospective Cohort Study in Japan
  著者名：Ohfuji S, Matsuura T, Tamori A, Kubo S, Sasaki S, Kondo K, Ito K, Fukushima W.
  出版物名：Dig Dis Sci. 2020 Jul 27. doi: 10.1007/s10620-020-06475-0. Online ahead of print.
• Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis
  著者名：Tseng CH, Hsu YC, Chen TH, Ji F, Chen IS, Tsai YN, Hai H, Thuy LTT, Hosaka T, Sezaki H, Borghi JA, Cheung R, Enomoto M, Nguyen MH.
  出版物名：Lancet Gastroenterol Hepatol. 2020 Dec;5(12):1039-1052. doi: 10.1016/S2468-1253(20)30249-1. Epub 2020 Sep 30.
• Pilot study of tenofovir disoproxil fumarate and pegylated interferon-alpha 2a add-on therapy in Japanese patients with chronic hepatitis B
  著者名：Matsumoto A, Nishiguchi S, Enomoto H, Tanaka Y, Shinkai N, Okuse C, Kang JH, Matsui T, Miyase S, Yatsuhashi H, Nagaoka S, Kanda T, Enomoto M, Yamada R, Hiramatsu N, Saito S, Takaguchi K, Ito K, Masaki T, Morihara D, Tsuge M, Chayama K, Ikeda F, Kagawa T, Kondo Y, Murata K, Tanaka E.
  出版物名：J Gastroenterol. 2020 Oct;55(10):977-989. doi: 10.1007/s00535-020-01707-6. Epub 2020 Jul 14.
• Comprehensive analysis of liver and blood miRNA in precancerous conditions
  著者名：Tomohiro Umezu, Koichi Tsuneyama, Kohsuke Kanekura, Michiyo Hayakawa, Toshihito Tanahashi, Mitsuoki Kawano, Y-H Taguchi, Hidenori Toyoda, Akihiro Tamori, Masahiko Kuroda, Yoshiki Murakami.
  出版物名：Sci Rep. 2020 Dec 10;10(1):21766. doi:10.1038/s41598-020-78500-1
• HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohort
  著者名：Yasuhito Tanaka, Eiichi Ogawa, Chung-Feng Huang, Hidenori Toyoda, Dae Won Jun, Cheng-Hao Tseng, Yao-Chun Hsu, Masaru Enomoto, Hirokazu Takahashi, Norihiro Furusyo, Ming-Lun Yeh, Etsuko Iio, Satoshi Yasuda, Carla Pui-Mei Lam, Dong Hyun Lee, Hiroaki Haga, Eileen L Yoon, Sang Bong Ahn, Grace Wong, Makoto Nakamuta, Hideyuki Nomura, Pei-Chien Tsai, Jang Han Jung, Do Seon Song, Hansen Dang, Mayumi Maeda, Linda Henry, Ramsey Cheung, Man-Fung Yuen, Yoshiyuki Ueno, Yuichiro Eguchi, Akihiro Tamori, Ming-Lung Yu, Jun Hayashi, Mindie H Nguyen, REAL-C Investigators
  出版物名：Hepatol Int. 2020 Dec 4. doi: 10.1007/s12072-020-10105-2. Online ahead of print.
• Anti-fibrotic treatments for chronic liver diseases: the present and the future
  著者名：Odagiri N, Matsubara T, Sato-Matsubara M, Fujii H, Enomoto M, Kawada N.
  出版物名：Clin Mol Hepatol. 2020 Dec 3. doi: 10.3350/cmh.2020.0187. Online ahead of print.

2020 和文

タイトル・著者

• 【肝線維化をめぐる最新情報】抗線維化薬開発の最新情報(総説/特集)
  著者名：松原三佐子、河田則文
  出版物名：日本消化器病学会雑誌（0446-6586）117巻１号 Page52-63（020.1）
• 【ここがキモ!いまはこうする　肝疾患vs.薬物療法　肝機能評価&薬物性肝障害マネジメントに強くなる】
  (第2章)肝障害を察知するための基礎知識　肝炎(解説/特集)
  著者名：小谷晃平、河田則文
  出版物名：薬事（0016-5980）62巻2号 Page237-244（2020.01）
• 【Post SVR時代の門脈圧亢進症】SVR後門脈圧亢進症の臨床像　門脈圧亢進症症例に対するDAAの選択(解説/特集)
  著者名：榎本大、田守昭博、河田則文
  出版物名：肝・胆・膵（0389-4991）80巻5号 Page809-815（2020.05）
• 【Post SVR時代の門脈圧亢進症】HCV SVR後の門脈圧亢進症診断　CTによる門脈圧亢進症の画像診断　(解説/特集）
  著者名：肝・胆・膵（0389-4991）80巻5号 Page769-779（2020.05）
  出版物名：山本晃（大阪市立大学 放射線診断学・IVR学）、打田佐和子、城後篤志、影山健、寒川悦次、植田大樹、河田則文、三木幸雄
• 慢性肝疾患における痒みの顕在化の工夫　慢性肝疾患診療におけるコメディカルとの連携（原著論文）
  著者名：打田佐和子[小林]、河田則文
  出版物名：日本高齢消化器病学会誌（1881-0837）22巻2号 Page6-10（2020.03）
• 【がん治療薬の副作用と支持療法】分子標的治療薬の副作用と支持療法　マルチキナーゼ阻害薬（解説/特集）
  著者名：萩原 淳司
  出版物名：腫瘍内科（1881-6568）25巻3号 Page246-250（2020.03）
• 【肝疾患の病態生理と新規治療法を巡る基礎的研究の動向】肝線維化の機序と新規治療(解説/特集)
  著者名：小田桐直志、元山宏行、河田則文
  出版物名：消化器・肝臓内科（2432-3446）7巻6号 Page514-521（2020.06）
• 【B型肝炎の再活性化:現状と撲滅に向けた対策】HBV再活性化対策のため介入投与された核酸アナログは中止可能か(解説/特集)
  著者名：田守 昭博、榎本 大、河田 則文
  出版物名：肝臓（0451-4203）61巻5号 Page244（2020.05）
• 後腹膜原発異所性肝細胞癌の1例（症例報告）
  著者名：林下晃士、打田佐和子、吉田香奈子、小田桐直志、小谷晃平、元山宏行、藤井英樹、萩原淳司、宮崎徹、西岡孝芳、新川寛二、田中肖吾、榎本大、田守昭博、久保正二、河田則文
  出版物名：
• 【線維化　慢性疾患のキープロセス　多彩な間質細胞が織りなす組織リモデリング"fibrosis"の理解】
  (第2章)線維化を制御する細胞間ネットワーク　肝星細胞の活性化におけるnon-coding RNAネットワーク (解説/特集）
  著者名：松原勤（大阪市立大学　大学院医学研究科　機能細胞形態学）、河田則文
  出版物名：実験医学（0288-5514）38巻12号Page2046-2052（2020.08）

論文一覧 バックナンバー

• 2021年
• 2020年
• 2019年
• 2018年
• 2017年
• 2016年
• 2015年
• 2014年
• 2013年
• 2012年
• 2011年
• 2010年
• 2009年
• 2008年
• 2007年
• 2006年
• 2005年